Side Effect Management in the Treatment of Multiple Myeloma

In this fourth issue, we will focus on the value of incorporating best practices for managing treatment-related toxicities. Subsequent issues will address the potential economic implications of novel agents used to treat myeloma-related bone complications and value-based benefit design considerations for the disease.